{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Allopurinol", "Ayurveda", "Boswellia", "Chinese medicine", "Crohn\u2019s disease", "Curcumin", "Inflammatory bowel disease", "Irritable bowel syndrome", "Omega-3 fatty acids", "Ulcerative colitis"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "28278495", "DateCompleted": {"Year": "2018", "Month": "03", "Day": "19"}, "DateRevised": {"Year": "2018", "Month": "11", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "03", "Day": "08"}], "Language": ["eng"], "ELocationID": ["10.1159/000468988"], "Journal": {"ISSN": "1423-0151", "JournalIssue": {"Volume": "26", "Issue": "3", "PubDate": {"Year": "2017"}}, "Title": "Medical principles and practice : international journal of the Kuwait University, Health Science Centre", "ISOAbbreviation": "Med Princ Pract"}, "ArticleTitle": "Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal.", "Pagination": {"StartPage": "201", "EndPage": "217", "MedlinePgn": "201-217"}, "Abstract": {"AbstractText": ["The gastrointestinal tract digests and absorbs dietary nutrients, protects the body against physical and chemical damage from contents in its lumen, provides immunity against external antigens, and keeps an optimum environment for the gut microbiota. These functions cannot be performed normally in several diseases of which the following are discussed here: irritable bowel syndrome and inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. Because these diseases are associated with oxidative stress, a host of antioxidant supplements are used for maintenance and recovery of the gut functions. However, the benefits of these supplements have not been established. The available 80 human trials were rated for levels of confidence and for benefits of the antioxidant supplements. For Crohn's disease, the supplements for which clear benefits occurred in at least 2 studies were allopurinol, Boswellia serrata (frankincense or shallaki), Artemesia species (wormwood), Tripterygium wilfordii (l\u00e9i g\u014dng t\u00e9ng), and omega-3 fatty acids. Similar beneficial supplements for ulcerative colitis were allopurinol, Matricaria chamomilla (chamomile), Curcuma longa (curcumin in turmeric), and omega-3 fatty acids. There was also a clear benefit for ulcerative colitis in 2 studies where a multiherbal Chinese medicine preparation and an Ayurvedic medicine preparation were used. For irritable bowel syndrome, there was only a marginal benefit of some of the antioxidant supplements. Thus, some antioxidant supplements may be beneficial at certain stages of specific diseases. This is consistent with the current concept that antioxidants act by inhibiting oxidative stress pathways in a tissue- and environment-specific manner and not by simply acting as scavengers."], "CopyrightInformation": "\u00a9 2017 S. Karger AG, Basel."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Kuwait University, Kuwait, Kuwait."}], "LastName": "Khan", "ForeName": "Islam", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Samson", "ForeName": "Sue E", "Initials": "SE"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Grover", "ForeName": "Ashok Kumar", "Initials": "AK"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Med Princ Pract", "NlmUniqueID": "8901334", "ISSNLinking": "1011-7571"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antioxidants"}, {"RegistryNumber": "0", "NameOfSubstance": "Fatty Acids, Omega-3"}, {"RegistryNumber": "63CZ7GJN5I", "NameOfSubstance": "Allopurinol"}], "CommentsCorrectionsList": [{"RefSource": "Med Princ Pract. 2017;26(4):397. doi: 10.1159/000477304", "PMID": "28535534"}, {"RefSource": "Med Princ Pract. 2017;26(4):398. doi: 10.1159/000477684", "PMID": "28715815"}], "MeshHeadingList": [{"QualifierName": ["therapeutic use"], "DescriptorName": "Allopurinol"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antioxidants"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Colitis, Ulcerative"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Crohn Disease"}, {"QualifierName": [], "DescriptorName": "Dietary Supplements"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Fatty Acids, Omega-3"}, {"QualifierName": ["physiology"], "DescriptorName": "Gastrointestinal Microbiome"}, {"QualifierName": ["physiopathology"], "DescriptorName": "Gastrointestinal Tract"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["diagnosis", "drug therapy"], "DescriptorName": "Inflammatory Bowel Diseases"}, {"QualifierName": ["diagnosis", "drug therapy"], "DescriptorName": "Irritable Bowel Syndrome"}, {"QualifierName": ["methods"], "DescriptorName": "Medicine, Traditional"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Chial HJ, Camilleri M. Gender differences in irritable bowel syndrome. J Gend Specif Med. 2002;5:37\u201345.", "ArticleIdList": ["12078061"]}, {"Citation": "Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46\u201354.", "ArticleIdList": ["22001864"]}, {"Citation": "Loftus EV., Jr Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504\u20131517.", "ArticleIdList": ["15168363"]}, {"Citation": "Lunney PC, Kariyawasam VC, Wang RR, et al. Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2015;42:61\u201370.", "ArticleIdList": ["25968332"]}, {"Citation": "Kamiya T. The overlap in the genetic pathogenesis of ulcerative colitis and irritable bowel syndrome. Dig Dis Sci. 2013;58:3379\u20133381.", "ArticleIdList": ["24233129"]}, {"Citation": "Miron N, Cristea V. Enterocytes: active cells in tolerance to food and microbial antigens in the gut. Clin Exp Immunol. 2012;167:405\u2013412.", "ArticleIdList": ["PMC3374272", "22288583"]}, {"Citation": "Birchenough GM, Johansson ME, Gustafsson JK, et al. New developments in goblet cell mucus secretion and function. Mucosal Immunol. 2015;8:712\u2013719.", "ArticleIdList": ["PMC4631840", "25872481"]}, {"Citation": "Clevers HC, Bevins CL. Paneth cells: maestros of the small intestinal crypts. Annu Rev Physiol. 2013;75:289\u2013311.", "ArticleIdList": ["23398152"]}, {"Citation": "Circu ML, Aw TY. Redox biology of the intestine. Free Radic Res. 2011;45:1245\u20131266.", "ArticleIdList": ["PMC3210416", "21831010"]}, {"Citation": "Hrncirova L, Krejsek J, Splichal I, et al. Crohn's disease: a role of gut microbiota and Nod2 gene polymorphisms in disease pathogenesis. Acta Medica (Hradec Kralove) 2014;57:89\u201396.", "ArticleIdList": ["25649363"]}, {"Citation": "Emerit J, Pelletier S, Tosoni-Verlignue D, et al. Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn's disease. Free Radic Biol Med. 1989;7:145\u2013149.", "ArticleIdList": ["2680784"]}, {"Citation": "Desai D, Shah S, Deshmukh A, et al. Colorectal cancers in ulcerative colitis from a low-prevalence area for colon cancer. World J Gastroenterol. 2015;21:3644\u20133649.", "ArticleIdList": ["PMC4375589", "25834332"]}, {"Citation": "Barrett JC, Lee JC, Lees CW, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009;41:1330\u20131334.", "ArticleIdList": ["PMC2812019", "19915572"]}, {"Citation": "Serban DE. Microbiota in inflammatory bowel disease pathogenesis and therapy: is it all about diet? Nutr Clin Pract. 2015;30:760\u2013779.", "ArticleIdList": ["26452390"]}, {"Citation": "Rokkas T, Gisbert JP, Niv Y, et al. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United European Gastroenterol J. 2015;3:539\u2013550.", "ArticleIdList": ["PMC4669512", "26668747"]}, {"Citation": "Dore MP, Goni E, Di Mario F. Is there a role for probiotics in Helicobacter pylori therapy? Gastroenterol Clin North Am. 2015;44:565\u2013575.", "ArticleIdList": ["26314668"]}, {"Citation": "Giorgetti G, Brandimarte G, Fabiocchi F, et al. Interactions between innate immunity, microbiota, and probiotics. J Immunol Res. 2015;2015:501361.", "ArticleIdList": ["PMC4451779", "26090492"]}, {"Citation": "Pandey V, Berwal V, Solanki N, et al. Probiotics: healthy bugs and nourishing elements of diet. J Int Soc Prev Community Dent. 2015;5:81\u201387.", "ArticleIdList": ["PMC4415334", "25992331"]}, {"Citation": "Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20:8867\u20138885.", "ArticleIdList": ["PMC4112893", "25083060"]}, {"Citation": "Ellinghaus D, Bethune J, Petersen BS, et al. The genetics of Crohn's disease and ulcerative colitis - status quo and beyond. Scand J Gastroenterol. 2015;50:13\u201323.", "ArticleIdList": ["25523552"]}, {"Citation": "Elmgreen J, Both H, Binder V. Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement. Gut. 1985;26:151\u2013157.", "ArticleIdList": ["PMC1432432", "3967833"]}, {"Citation": "Sanford P. Crohn's disease or ulcerative colitis? Check your patient's symptoms. Gastroenterol Nurs. 1990;12:204.", "ArticleIdList": ["2288927"]}, {"Citation": "Brookes MJ, Green JR. Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Drugs. 2004;64:1069\u20131089.", "ArticleIdList": ["15139787"]}, {"Citation": "Burger M, Schmidt C, Teich N, et al. Medical therapy of active ulcerative colitis. Viszeralmedizin. 2015;31:236\u2013245.", "ArticleIdList": ["PMC4608602", "26557831"]}, {"Citation": "Vermeire S. Oral SMAD7 antisense drug for Crohn's disease. N Engl J Med. 2015;372:1166\u20131167.", "ArticleIdList": ["25785975"]}, {"Citation": "Monteleone G, Pallone F. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015;372:2461.", "ArticleIdList": ["26083213"]}, {"Citation": "Halliwell B. The chemistry of free radicals. Toxicol Ind Health. 1993;9:1\u201321.", "ArticleIdList": ["8380303"]}, {"Citation": "Fridovich I. Oxygen: how do we stand it? Med Princ Pract. 2013;22:131\u2013137.", "ArticleIdList": ["PMC5685332", "22759590"]}, {"Citation": "Liochev SI. Free radicals: how do we stand them? Anaerobic and aerobic free radical (chain) reactions involved in the use of fluorogenic probes and in biological systems. Med Princ Pract. 2014;23:195\u2013203.", "ArticleIdList": ["PMC5586870", "24356000"]}, {"Citation": "Walia M, Kwan CY, Grover AK. Effects of free radicals on coronary artery. Med Princ Pract. 2003;12:1\u20139.", "ArticleIdList": ["12566961"]}, {"Citation": "Couto N, Wood J, Barber J. The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free Radic Biol Med. 2016;95:27\u201342.", "ArticleIdList": ["26923386"]}, {"Citation": "Forman HJ, Davies KJ, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic Biol Med. 2014;66:24\u201335.", "ArticleIdList": ["PMC3852196", "23747930"]}, {"Citation": "Nkabyo YS, Ziegler TR, Gu LH, et al. Glutathione and thioredoxin redox during differentiation in human colon epithelial (Caco-2) cells. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1352\u2013G1359.", "ArticleIdList": ["12433666"]}, {"Citation": "Balmus IM, Ciobica A, Trifan A, et al. The implications of oxidative stress and antioxidant therapies in inflammatory bowel disease: clinical aspects and animal models. Saudi J Gastroenterol. 2016;22:3\u201317.", "ArticleIdList": ["PMC4763525", "26831601"]}, {"Citation": "Piechota-Polanczyk A, Fichna J. Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:605\u2013620.", "ArticleIdList": ["PMC4065336", "24798211"]}, {"Citation": "Boyanapalli SS, Paredes-Gonzalez X, Fuentes F, et al. Nrf2 knockout attenuates the anti-inflammatory effects of phenethyl isothiocyanate and curcumin. Chem Res Toxicol. 2014;27:2036\u20132043.", "ArticleIdList": ["PMC4269407", "25387343"]}, {"Citation": "Soetikno V, Sari FR, Lakshmanan AP, et al. Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway. Mol Nutr Food Res. 2013;57:1649\u20131659.", "ArticleIdList": ["23174956"]}, {"Citation": "Ding Y, Chen M, Wang M, et al. Neuroprotection by acetyl-11-keto-\u03b2-boswellic acid, in ischemic brain injury involves the Nrf2/HO-1 defense pathway. Sci Rep. 2014;4:7002.", "ArticleIdList": ["PMC4227012", "25384416"]}, {"Citation": "Fetoni AR, Paciello F, Rolesi R, et al. Rosmarinic acid up-regulates the noise-activated Nrf2/HO-1 pathway and protects against noise-induced injury in rat cochlea. Free Radic Biol Med. 2015;85:269\u2013281.", "ArticleIdList": ["25936352"]}, {"Citation": "Howitz KT, Sinclair DA. Xenohormesis: sensing the chemical cues of other species. Cell. 2008;133:387\u2013391.", "ArticleIdList": ["PMC2504011", "18455976"]}, {"Citation": "Masri OA, Chalhoub JM, Sharara AI. Role of vitamins in gastrointestinal diseases. World J Gastroenterol. 2015;21:5191\u20135209.", "ArticleIdList": ["PMC4419060", "25954093"]}, {"Citation": "Lan A, Blachier F, Benamouzig R, et al. Mucosal healing in inflammatory bowel diseases: is there a place for nutritional supplementation? Inflamm Bowel Dis. 2015;21:198\u2013207.", "ArticleIdList": ["25208104"]}, {"Citation": "Bi L, Triadafilopoulos G. Exercise and gastrointestinal function and disease: an evidence-based review of risks and benefits. Clin Gastroenterol Hepatol. 2003;1:345\u2013355.", "ArticleIdList": ["15017652"]}, {"Citation": "Curkovic I, Rentsch KM, Frei P, et al. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. Eur J Clin Pharmacol. 2013;69:1521\u20131531.", "ArticleIdList": ["23588559"]}, {"Citation": "Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363\u2013369.", "ArticleIdList": ["22605661"]}, {"Citation": "Seinen ML, de Boer NK, Smid K, et al. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series. Nucleosides Nucleotides Nucleic Acids. 2011;30:1085\u20131090.", "ArticleIdList": ["22132961"]}, {"Citation": "Salim AS. Role of oxygen-derived free radical scavengers in the management of recurrent attacks of ulcerative colitis: a new approach. J Lab Clin Med. 1992;119:710\u2013717.", "ArticleIdList": ["1350610"]}, {"Citation": "Jarnerot G, Strom M, Danielsson A, et al. Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis. Aliment Pharmacol Ther. 2000;14:1159\u20131162.", "ArticleIdList": ["10971232"]}, {"Citation": "Gerhardt H, Seifert F, Buvari P, et al. Therapy of active Crohn disease with Boswellia serrata extract H 15 (in German) Z Gastroenterol. 2001;39:11\u201317.", "ArticleIdList": ["11215357"]}, {"Citation": "Gupta PK, Samarakoon SM, Chandola HM, Ravishankar B. Clinical evaluation of Boswellia serrata (Shallaki) resin in the management of Sandhivata (osteoarthritis) Ayu. 2011;32:478\u2013482.", "ArticleIdList": ["PMC3361921", "22661840"]}, {"Citation": "Miller JM, Goodell HB. Frankincense and myrrh. Surg Gynecol Obstet. 1968;127:360\u2013365.", "ArticleIdList": ["4874130"]}, {"Citation": "Madisch A, Miehlke S, Eichele O, et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis. 2007;22:1445\u20131451.", "ArticleIdList": ["17764013"]}, {"Citation": "Slonim AE, Grovit M, Bulone L. Effect of exclusion diet with nutraceutical therapy in juvenile Crohn's disease. J Am Coll Nutr. 2009;28:277\u2013285.", "ArticleIdList": ["20150601"]}, {"Citation": "Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med. 2001;67:391\u2013395.", "ArticleIdList": ["11488449"]}, {"Citation": "Bundy R, Walker AF, Middleton RW, et al. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med. 2004;10:1015\u20131018.", "ArticleIdList": ["15673996"]}, {"Citation": "Lang A, Salomon N, Wu JC, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13:1444\u20131449.", "ArticleIdList": ["25724700"]}, {"Citation": "Singla V, Pratap M, Garg SK, et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study. J Crohns Colitis. 2014;8:208\u2013214.", "ArticleIdList": ["24011514"]}, {"Citation": "Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191\u20132193.", "ArticleIdList": ["16240238"]}, {"Citation": "Suskind DL, Wahbeh G, Burpee T, et al. Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr. 2013;56:277\u2013279.", "ArticleIdList": ["PMC3701433", "23059643"]}, {"Citation": "Srivastava JK, Shankar E, Gupta S. Chamomile: a herbal medicine of the past with bright future. Mol Med Rep. 2010;3:895\u2013901.", "ArticleIdList": ["PMC2995283", "21132119"]}, {"Citation": "Langhorst J, Frede A, Knott M, et al. Distinct kinetics in the frequency of peripheral CD4+ T cells in patients with ulcerative colitis experiencing a flare during treatment with mesalazine or with a herbal preparation of myrrh, chamomile, and coffee charcoal. PLoS One. 2014;9:e104257.", "ArticleIdList": ["PMC4140685", "25144293"]}, {"Citation": "Langhorst J, Varnhagen I, Schneider SB, et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis - a double-blind, double-dummy study. Aliment Pharmacol Ther. 2013;38:490\u2013500.", "ArticleIdList": ["23826890"]}, {"Citation": "Altunkaya A, Y\u00fdld\u00fdr\u00fdm B, Ekici K, et al. Determining essential oil composition, antibacterial and antioxidant activity of water wormwood extracts. GIDA. 2014;39:17\u201324."}, {"Citation": "Omer B, Krebs S, Omer H, et al. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine. 2007;14:87\u201395.", "ArticleIdList": ["17240130"]}, {"Citation": "Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - a controlled clinical trial. Phytomedicine. 2010;17:305\u2013309.", "ArticleIdList": ["19962291"]}, {"Citation": "Riachi LG, De Maria CA. Peppermint antioxidants revisited. Food Chem. 2015;176:72\u201381.", "ArticleIdList": ["25624208"]}, {"Citation": "Liu JH, Chen GH, Yeh HZ, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. 1997;32:765\u2013768.", "ArticleIdList": ["9430014"]}, {"Citation": "Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J. 1979;2:835\u2013836.", "ArticleIdList": ["PMC1596628", "389344"]}, {"Citation": "Alam MS, Roy PK, Miah AR, et al. Efficacy of peppermint oil in diarrhea predominant. Mymensingh Med J. 2013;22:27\u201330.", "ArticleIdList": ["23416804"]}, {"Citation": "Cappello G, Spezzaferro M, Grossi L, et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. 2007;39:530\u2013536.", "ArticleIdList": ["17420159"]}, {"Citation": "Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 2016;61:560\u2013571.", "ArticleIdList": ["PMC4729798", "26319955"]}, {"Citation": "Merat S, Khalili S, Mostajabi P, et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci. 2010;55:1385\u20131390.", "ArticleIdList": ["19507027"]}, {"Citation": "Romano C, Cucchiara S, Barabino A, et al. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol. 2005;11:7118\u20137121.", "ArticleIdList": ["PMC4725070", "16437657"]}, {"Citation": "Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med. 1996;334:1557\u20131560.", "ArticleIdList": ["8628335"]}, {"Citation": "Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA. 2008;299:1690\u20131697.", "ArticleIdList": ["18398081"]}, {"Citation": "Stenson WF, Cort D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med. 1992;116:609\u2013614.", "ArticleIdList": ["1312317"]}, {"Citation": "Barbosa DS, Cecchini R, El Kadri MZ, et al. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition. 2003;19:837\u2013842.", "ArticleIdList": ["14559317"]}, {"Citation": "Dichi I, Frenhane P, Dichi JB, et al. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. Nutrition. 2000;16:87\u201390.", "ArticleIdList": ["10696629"]}, {"Citation": "Ren J, Wu X, Liao N, et al. Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine. J Int Med Res. 2013;41:176\u2013187.", "ArticleIdList": ["23569144"]}, {"Citation": "Tao QS, Ren JA, Ji ZL, et al. Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease (in Chinese) Zhonghua Wei Chang Wai Ke Za Zhi. 2009;12:491\u2013493.", "ArticleIdList": ["19742342"]}, {"Citation": "Liao NS, Ren JA, Fan CG, et al. Efficacy of polyglycosides of Tripterygium wilfordii in preventing postoperative recurrence of Crohn disease (in Chinese) Zhonghua Wei Chang Wai Ke Za Zhi. 2009;12:167\u2013169.", "ArticleIdList": ["19296254"]}, {"Citation": "Zhu W, Li Y, Gong J, et al. Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. Dig Liver Dis. 2015;47:14\u201319.", "ArticleIdList": ["25445405"]}, {"Citation": "Fukunaga K, Ohda Y, Hida N, et al. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J Gastroenterol Hepatol. 2012;27:1808\u20131815.", "ArticleIdList": ["22775479"]}, {"Citation": "Patel KB, Patel M, Mehta CS, et al. Ayurvedic management of ulcerative colitis - a non-randomized observational clinical study. Forsch Komplementmed. 2013;20:144\u2013147.", "ArticleIdList": ["23636034"]}, {"Citation": "Joelsson M, Andersson M, Bark T, et al. Allopurinol as prophylaxis against pouchitis following ileal pouch-anal anastomosis for ulcerative colitis. A randomized placebo- controlled double-blind study. Scand J Gastroenterol. 2001;36:1179\u20131184.", "ArticleIdList": ["11686218"]}, {"Citation": "Davis K, Philpott S, Kumar D, et al. Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. Int J Clin Pract. 2006;60:1080\u20131086.", "ArticleIdList": ["16749917"]}, {"Citation": "Hutchings HA, Wareham K, Baxter JN, et al. A randomised, cross-over, placebo-controlled study of Aloe vera in patients with irritable bowel syndrome: effects on patient quality of life. ISRN Gastroenterol. 2011;2011:206103.", "ArticleIdList": ["PMC3168391", "21991499"]}, {"Citation": "Khedmat H, Karbasi A, Amini M, et al. Aloe vera in treatment of refractory irritable bowel syndrome: trial on Iranian patients. J Res Med Sci. 2013;18:732.", "ArticleIdList": ["PMC3872617", "24379854"]}, {"Citation": "Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 2004;19:739\u2013747.", "ArticleIdList": ["15043514"]}, {"Citation": "Tang T, Targan SR, Li ZS, et al. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther. 2011;33:194\u2013202.", "ArticleIdList": ["21114791"]}, {"Citation": "Sandborn WJ, Targan SR, Byers VS, et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013;108:90\u201398.", "ArticleIdList": ["PMC3538174", "23044768"]}, {"Citation": "Hawrelak JA, Myers SP. Effects of two natural medicine formulations on irritable bowel syndrome symptoms: a pilot study. J Altern Complement Med. 2010;16:1065\u20131071.", "ArticleIdList": ["20954962"]}, {"Citation": "Biedermann L, Mwinyi J, Scharl M, et al. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study. J Crohns Colitis. 2013;7:271\u2013279.", "ArticleIdList": ["22883440"]}, {"Citation": "Holtmeier W, Zeuzem S, Preiss J, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis. 2011;17:573\u2013582.", "ArticleIdList": ["20848527"]}, {"Citation": "Bortolotti M, Porta S. Effect of red pepper on symptoms of irritable bowel syndrome: preliminary study. Dig Dis Sci. 2011;56:3288\u20133295.", "ArticleIdList": ["21573941"]}, {"Citation": "Schmulson MJ, Valdovinos MA, et al. Chili pepper and rectal hyperalgesia in irritable bowel syndrome. Am J Gastroenterol. 2003;98:1214\u20131215.", "ArticleIdList": ["12809862"]}, {"Citation": "Bortolotti M, Coccia G, Grossi G, et al. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther. 2002;16:1075\u20131082.", "ArticleIdList": ["12030948"]}, {"Citation": "Baraniuk JN, El Amin S, Corey R, et al. Carnosine treatment for Gulf War illness: a randomized controlled trial. Glob J Health Sci. 2013;5:69\u201381.", "ArticleIdList": ["PMC4209301", "23618477"]}, {"Citation": "Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005;40:1058\u20131065.", "ArticleIdList": ["16165718"]}, {"Citation": "Dryden GW, Lam A, Beatty K, et al. A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis. Inflamm Bowel Dis. 2013;19:1904\u20131912.", "ArticleIdList": ["23846486"]}, {"Citation": "Chang CC, Lin YT, Lu YT, et al. Kiwifruit improves bowel function in patients with irritable bowel syndrome with constipation. Asia Pac J Clin Nutr. 2010;19:451\u2013457.", "ArticleIdList": ["21147704"]}, {"Citation": "Kaliora AC, Stathopoulou MG, Triantafillidis JK, et al. Chios mastic treatment of patients with active Crohn's disease. World J Gastroenterol. 2007;13:748\u2013753.", "ArticleIdList": ["PMC4066008", "17278198"]}, {"Citation": "Guijarro LG, Mate J, Gisbert JP, et al. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. World J Gastroenterol. 2008;14:2851\u20132857.", "ArticleIdList": ["PMC2710726", "18473409"]}, {"Citation": "Bauditz J, Haemling J, Ortner M, et al. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut. 1997;40:470\u2013474.", "ArticleIdList": ["PMC1027120", "9176073"]}, {"Citation": "Kline RM, Kline JJ, Di Palma J, et al. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001;138:125\u2013128.", "ArticleIdList": ["11148527"]}, {"Citation": "Kamali M, Tavakoli H, Khodadoost M, et al. Efficacy of the Punica granatum peels aqueous extract for symptom management in ulcerative colitis patients. A randomized, placebo-controlled, clinical trial. Complement Ther Clin Pract. 2015;21:141\u2013146.", "ArticleIdList": ["26256131"]}, {"Citation": "Tomas-Ridocci M, Anon R, Minguez M, et al. The efficacy of Plantago ovata as a regulator of intestinal transit. A double-blind study compared to placebo (in Spanish) Rev Esp Enferm Dig. 1992;82:17\u201322.", "ArticleIdList": ["1520545"]}, {"Citation": "Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU) Am J Gastroenterol. 1999;94:427\u2013433.", "ArticleIdList": ["10022641"]}, {"Citation": "Kolacek M, Muchova J, Dvorakova M, et al. Effect of natural polyphenols (Pycnogenol) on oxidative stress markers in children suffering from Crohn's disease - a pilot study. Free Radic Res. 2013;47:624\u2013634.", "ArticleIdList": ["23710677"]}, {"Citation": "Samsami-Kor M, Daryani NE, Asl PR, et al. Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res. 2015;46:280\u2013285.", "ArticleIdList": ["26002728"]}, {"Citation": "Emerit J, Pelletier S, Likforman J, et al. Phase II trial of copper zinc superoxide dismutase (CuZn SOD) in the treatment of Crohn's disease. Free Radic Res Commun. 1991;12-13:563\u2013569.", "ArticleIdList": ["2060833"]}, {"Citation": "Huber R, Ditfurth AV, Amann F, et al. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol. 2007;41:834\u2013838.", "ArticleIdList": ["17881930"]}, {"Citation": "Lehmann M, Walther M, Ulitzsch S, Thomas A, Hauser W, Stallmach A. Validation and first results of the German QUOTE-IBD to measure quality of care from the perspective of patients with inflammatory bowel disease (in German) Z Gastroenterol. 2013;51:196\u2013203.", "ArticleIdList": ["23417364"]}, {"Citation": "Lahiff C, Safaie P, Awais A, et al. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2013;37:786\u2013794.", "ArticleIdList": ["23432394"]}, {"Citation": "Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID) Gut. 1989;30:983\u2013989.", "ArticleIdList": ["PMC1434265", "2668130"]}, {"Citation": "Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395\u2013402.", "ArticleIdList": ["9146781"]}, {"Citation": "Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29\u201332.", "ArticleIdList": ["PMC1727189", "9771402"]}, {"Citation": "Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105:2218\u20132227.", "ArticleIdList": ["PMC3180711", "20517305"]}, {"Citation": "Lorenz-Meyer H, Bauer P, Nicolay C, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group) Scand J Gastroenterol. 1996;31:778\u2013785.", "ArticleIdList": ["8858747"]}, {"Citation": "Nielsen AA, Nielsen JN, Gronbaek H, et al. Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin levels and nutritional status in active Crohn's disease treated with prednisolone. Digestion. 2007;75:10\u201316.", "ArticleIdList": ["17429201"]}, {"Citation": "Geerling BJ, Badart-Smook A, van Deursen C, et al. Nutritional supplementation with n-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis. 2000;6:77\u201384.", "ArticleIdList": ["10833065"]}, {"Citation": "Nielsen AA, Jorgensen LG, Nielsen JN, et al. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. Aliment Pharmacol Ther. 2005;22:1121\u20131128.", "ArticleIdList": ["16305726"]}, {"Citation": "Eivindson M, Gronbaek H, Nielsen JN, et al. Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with omega-3 or omega-6 fatty acids and corticosteroids. Scand J Gastroenterol. 2005;40:1214\u20131221.", "ArticleIdList": ["16265778"]}, {"Citation": "Brunborg LA, Madland TM, Lind RA, et al. Effects of short-term oral administration of dietary marine oils in patients with inflammatory bowel disease and joint pain: a pilot study comparing seal oil and cod liver oil. Clin Nutr. 2008;27:614\u2013622.", "ArticleIdList": ["18374458"]}, {"Citation": "Bjorkkjaer T, Brunborg LA, Arslan G, et al. Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil. Scand J Gastroenterol. 2004;39:1088\u20131094.", "ArticleIdList": ["15545167"]}, {"Citation": "Almallah YZ, Richardson S, O'Hanrahan T, et al. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol. 1998;93:804\u2013809.", "ArticleIdList": ["9625132"]}, {"Citation": "Almallah YZ, El Tahir A, Heys SD, et al. Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition. Eur J Clin Invest. 2000;30:58\u201365.", "ArticleIdList": ["10620003"]}, {"Citation": "Almallah YZ, Ewen SW, El Tahir A, et al. Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ. J Clin Immunol. 2000;20:68\u201376.", "ArticleIdList": ["10798610"]}, {"Citation": "Seidner DL, Lashner BA, Brzezinski A, et al. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3:358\u2013369.", "ArticleIdList": ["15822041"]}, {"Citation": "Salomon P, Kornbluth AA, Janowitz HD. Treatment of ulcerative colitis with fish oil n-3-omega-fatty acid: an open trial. J Clin Gastroenterol. 1990;12:157\u2013161.", "ArticleIdList": ["2109004"]}, {"Citation": "Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA. 1998;280:1585\u20131589.", "ArticleIdList": ["9820260"]}, {"Citation": "Bensoussan A, Kellow JE, Bourchier SJ, et al. Efficacy of a Chinese herbal medicine in providing adequate relief of constipation-predominant irritable bowel syndrome: a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13:1946\u20131954.", "ArticleIdList": ["26133902"]}, {"Citation": "Liang ZF, Chen RH, Xu YS, et al. Tiaohe Ganpi Hexin Decoction in treatment of irritable bowel syndrome with diarrhea: a randomized controlled trial (in Chinese) Zhong Xi Yi Jie He Xue Bao. 2009;7:819\u2013822.", "ArticleIdList": ["19747435"]}, {"Citation": "Gao WY, Lin YF, Chen SQ, et al. Effects of Changjishu soft elastic capsule in treatment of diarrhea-predominant irritable bowel patients with liver-qi stagnation and spleen deficiency syndrome: a randomized double-blinded controlled trial (in Chinese) Zhong Xi Yi Jie He Xue Bao. 2009;7:212\u2013217.", "ArticleIdList": ["19284948"]}, {"Citation": "Leung WK, Wu JC, Liang SM, et al. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial. Am J Gastroenterol. 2006;101:1574\u20131580.", "ArticleIdList": ["16863563"]}, {"Citation": "Xie ZH, Wang TJ, Zheng YX, et al. Shuxuening injection combined with routine therapy in treating patients with active ulcerative colitis: an analysis of efficacy (in Chinese) Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014;34:1164\u20131167.", "ArticleIdList": ["25509255"]}, {"Citation": "Tiwari R, Pandya DH, Baghel MS. Clinical evaluation of Bilvadileha in the management of irritable bowel syndrome. Ayu. 2013;34:368\u2013372.", "ArticleIdList": ["PMC3968698", "24696573"]}, {"Citation": "Yadav SK, Jain AK, Tripathi SN, et al. Irritable bowel syndrome: therapeutic evaluation of indigenous drugs. Indian J Med Res. 1989;90:496\u2013503.", "ArticleIdList": ["2697693"]}]}], "History": [{"Year": "2016", "Month": "5", "Day": "31"}, {"Year": "2017", "Month": "3", "Day": "8"}, {"Year": "2017", "Month": "3", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "3", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "3", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "3", "Day": "8"}], "PublicationStatus": "ppublish", "ArticleIdList": ["28278495", "PMC5588418", "10.1159/000468988", "000468988"]}}]}